FDA Approves Mirvetuximab Soravtansine-gynx for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer – The ASCO Post
On March 22, the U.S. Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior syst emic treatment regimens. Patients are selected for treatment with mirvetuximab soravtansine based on an FDA-approved test. Mirvetuximab soravtansine previously received accelerated approval for this indication.